Literature DB >> 17398017

Can a subgroup of node-negative breast carcinoma patients with T1-2 tumor who may benefit from postmastectomy radiotherapy be identified?

Emin Yildirim1, Ugur Berberoglu.   

Abstract

PURPOSE: To determine a subgroup of T1-2N0 breast carcinoma patients at high risk for local recurrence. METHODS AND MATERIALS: In this retrospective study, univariate and multivariate prognostic factor analyses for local recurrence and distant recurrence were carried out in 502 patients.
RESULTS: During the median observation time of 77 months (range, 24-191 months), 14 patients (2.8%) had local recurrence and 55 (11.0%) had distant recurrence. Tumor size (continuous, p = 0.03; hazard ratio [HR] 1.2; 95% confidence interval [CI], 1.1-1.7), grade (p = 0.01; HR, 2.4; 95% CI, 1.2-5.0), lymphatic vascular invasion (LVI) (p = 0.01; HR, 10.0; 95% CI, 2.4-17.3), estrogen receptor status (p = 0.01; HR, 6.3; 95% CI, 2.0-23.0) and cErbB2 status (p = 0.01; HR, 10.0; 95% CI 1.8-87.5) were strongly associated with distant recurrence. Tumor size (< or =2 cm vs. >2 cm; p = 0.05; HR, 5.4; 95% CI, 1.2-28.0) and LVI (p = 0.004; HR, 9.0; 95% CI, 2.0-41.0) in patients aged < or =40 years, and tumor size (< or =3 cm vs. >3 cm; p = 0.05; HR 8.6; 95% CI 1.3-75.0), LVI (p = 0.007; HR, 18.0; 95% CI, 2.1-153.0), and grade (p = 0.05; HR, 7.0; 95% CI, 1.2-63.0) in patients aged >40 years were the most important predictive factors for local recurrence.
CONCLUSIONS: Among breast carcinoma patients, young patients with tumor size >2 cm and LVI and older patients with tumor size >3 cm, LVI, and high-grade tumor had a high risk of local recurrence.

Entities:  

Mesh:

Year:  2007        PMID: 17398017     DOI: 10.1016/j.ijrobp.2007.01.015

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy.

Authors:  Rita Abi-Raad; Rimoun Boutrus; Rui Wang; Andrzej Niemierko; Shannon Macdonald; Barbara Smith; Alphonse G Taghian
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-03-21       Impact factor: 7.038

2.  Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy.

Authors:  Ranjna Sharma; Isabelle Bedrosian; Anthony Lucci; Rosa F Hwang; Loren L Rourke; Wei Qiao; Thomas A Buchholz; Steven J Kronowitz; Savitri Krishnamurthy; Gildy V Babiera; Ana M Gonzalez-Angulo; Funda Meric-Bernstam; Elizabeth A Mittendorf; Kelly K Hunt; Henry M Kuerer
Journal:  Ann Surg Oncol       Date:  2010-05-05       Impact factor: 5.344

3.  Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?

Authors:  Anita Mamtani; Sujata Patil; Michelle M Stempel; Monica Morrow
Journal:  Cancer       Date:  2017-03-23       Impact factor: 6.860

4.  Irradiation after surgery for breast cancer patients with primary tumours and one to three positive axillary lymph nodes: yes or no?

Authors:  C Lu; H Xu; X Chen; Z Tong; X Liu; Y Jia
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

5.  Radiotherapy can improve the disease-free survival rate in triple-negative breast cancer patients with T1-T2 disease and one to three positive lymph nodes after mastectomy.

Authors:  Xingxing Chen; Xiaoli Yu; Jiayi Chen; Zhaozhi Yang; Zhimin Shao; Zhen Zhang; Xiaomao Guo; Yan Feng
Journal:  Oncologist       Date:  2013-01-18

6.  Possible benefits from post-mastectomy radiotherapy in node-negative breast cancer patients: a multicenter analysis in Korea (KROG 14-22).

Authors:  Hae Jin Park; Kyung Hwan Shin; Jin Ho Kim; Seung Do Ahn; Su Ssan Kim; Yong Bae Kim; Won Park; Yeon-Joo Kim; Hyun Soo Shin; Jin Hee Kim; Sun Young Lee; Kyubo Kim; Kyung Ran Park; Bae Kwon Jeong
Journal:  Oncotarget       Date:  2017-03-15

7.  Can a subgroup at high risk for LRR be identified from T1-2 breast cancer with negative lymph nodes after mastectomy? A meta-analysis.

Authors:  Gongling Peng; Zhuohui Zhou; Ming Jiang; Fan Yang
Journal:  Biosci Rep       Date:  2019-09-20       Impact factor: 3.840

8.  Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.

Authors:  Hesham Elghazaly; Hope S Rugo; Hamdy A Azim; Sandra M Swain; Banu Arun; Matti Aapro; Edith A Perez; Benjamin O Anderson; Frederique Penault-Llorca; Pierfranco Conte; Nagi S El Saghir; Cheng-Har Yip; Marwan Ghosn; Philip Poortmans; Mohamed A Shehata; Armando E Giuliano; Jessica W T Leung; Valentina Guarneri; Joseph Gligorov; Bahadir M Gulluoglu; Hany Abdel Aziz; Mona Frolova; Mohamed Sabry; Charles M Balch; Roberto Orecchia; Heba M El-Zawahry; Sana Al-Sukhun; Khaled Abdel Karim; Alaa Kandil; Ruslan M Paltuev; Meteb Foheidi; Mohamed El-Shinawi; Manal ElMahdy; Omalkhair Abulkhair; Wentao Yang; Adel T Aref; Joaira Bakkach; Nermean Bahie Eldin; Hagar Elghazawy
Journal:  Cancers (Basel)       Date:  2021-05-08       Impact factor: 6.639

Review 9.  Managing breast cancer in younger women: challenges and solutions.

Authors:  Foluso O Ademuyiwa; Amy Cyr; Jennifer Ivanovich; Maria A Thomas
Journal:  Breast Cancer (Dove Med Press)       Date:  2015-12-21

Review 10.  Clinical decision making in postmastectomy radiotherapy in node negative breast cancer.

Authors:  Rodrigo Barrientos; Suraj Samtani; Michael Frelinghuysen; Camilo Sotomayor; Juan Guillermo Gormaz; Mauricio Burotto
Journal:  Ecancermedicalscience       Date:  2018-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.